submit to the journals

Dermatological Cancer Journal Articles, Videos And Insights

Dermatological Cancer:FEATURED Articles

flipper_slider

Dermatological Cancer: Latest Articles

Dermatological Cancer: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Adjuvant use of Immune Checkpoint Inhibitors After Resection of Advanced Melanoma Katrina Mountfort
Medical Writer, Touch Medical Media, UK

Dermatological Cancer:FEATURED VIDEOS

Editor's choice

touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this patient population. 1. What are the limitations of ipilimumab as adjuvant therapy in patients with resected stage III melanoma? (0:11) 2. What is the current prognosis for patients with resected stage III or IV melanoma? (1:28) 3. What are the aims of the CheckMate 238 study? (2:51) 4. What have been the efficacy findings of the study to date? (3:31) 5. How does the safety profile of nivolumab compare to that of ipilimumab in this patient population? (4:36) Speaker disclosures: Jeffrey S Weber has nothing to disclose in relation to this video interview. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018 Read our Insight coverage here.
Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment. 1. How are personalised strategies impacting the treatment of melanoma? (0:11) 2. What molecular markers have been validated to inform selection of therapy? (1:04) 3. What is the main focus of current research investigating combinations of therapy in melanoma? (2:16) 4. What have been the latest advances in systemic adjuvant treatment of stage II/III melanoma? (4:20) 5. What do you see as the most important advance in melanoma treatment in recent years? (5:35) Speaker disclosures: Paolo Ascierto has provided an advisory role for BMS, Roche, MSD, Array, Novartis, Amgen, EMD Serono, Pierre-Fabre, Incyte, Genmad, New Link Genetics, Medimmune, AstraZeneca and Sindax. He has also received research funds from BMS, Roche and Array. Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Dermatological Cancer:Latest Videos

Video List based on Category on Node Page

Latest Videos

touchONCOLOGY talks to Jeffrey S Weber from the Laura and Isaac Perlmutter Cancer Cente and NYU Langone Medical Center about the limitations of ipilimumab for the treatment of resected stage III melanoma and how the findings of the CheckMate238 trial can improve the safety profile of this...
Editorial board member Paolo Ascierto from National Tumor Institute “Fondazione G. Pascale”, Naples, Italy, discusses the use of molecular markers to inform therapy in melanoma and important research approaches to advance treatment. 1. How are personalised strategies impacting the...
Jean-Jacques Grob discusses the role of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the greatest controversies? 0:07 2. What is the...
Ivan Marquez Rodas discusses the unmet treatment needs in melanoma, and the benefits of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the...
Dirk Schadendorf discusses the unmet need and importance, benefits and timing of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the...
Mario Mandala discusses the importance, benefits and timing of adjuvant therapy in the treatment of melanoma at ESMO 2017. Support: The filming of this video was supported by Novartis. 1. What are the most significant unmet needs in melanoma treatment? And what are the greatest controversies?...

LATEST TWEETS

Conference Highlights